Sporanox for Cancer Treatment?

Thursday, September 5th, 2013

HedgePath Pharmaceuticals has recently signed a supply and license agreement with Australia-based Mayne Pharma to develop a formulation of itraconazole (Sporanox) for treating a range of cancer. This formulation is called SUBA-itraconazole, and the focus of this deal will be on getting marketing and regulatory approval in the United States. HedgePath is currently repurposing itraconazole, […]

Sporanox and Other Medications May Interact with New Saxagliptin

Monday, July 1st, 2013

AstraZeneca and Bristol-Myers recently announced top line results for the Phase 4 SAVOR-TIMI-53 trial (saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus). In the results published, it was found that the new drug Onglyza (generic name saxagliptin) may interact with strong CYP3A4/5 inhibitors like itraconazole (brand name Sporanox) and others like atazanavir, […]

Sporanox Linked to Early Peripheral Neuropathy among Myeloma Patients

Monday, June 10th, 2013

A Japanese study suggests that sporanox, a medicine indicated for fungal infection treatment, may raise the risk of peripheral neuropathy in multiple myeloma patients undergoing treatment with bortezomib. Peripheral neuropathy is a side effect associated with bortezomib and characterized by tingling or pain in the extremities. It is caused by nerve damage. Researchers of this […]